Cl-NQTrp
Modify Date: 2024-01-17 18:12:50
Cl-NQTrp structure
|
Common Name | Cl-NQTrp | ||
|---|---|---|---|---|
| CAS Number | 185351-23-9 | Molecular Weight | 394.81 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H15ClN2O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Cl-NQTrpCl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein[1][2]. |
| Name | Cl-NQTrp |
|---|
| Description | Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Cl-NQTrp efciently disassembled pre-formed PHF6 peptide fbrils[1]. Cl-NQTrp has the potential to induce conformational changes in PHF6 peptide oligomers[1]. |
| In Vivo | Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau[2]. Cl-NQTrp significantly alleviates the shorter life span of htau-expressing flies, leading to 58% viability on day 29[2]. Animal Model: Virgin females, carrying either the eye GMR -Gal4 driver or the pan-neuronal driver elavc155 -Gal4 on chromosome X, were collected and crossed with males carrying UAS-h tau on the 2nd chromosome or with wild-type Oregon-R (OR) males as a control[2]. Dosage: 0.75 mg/mL. Administration: Dripped every other day. Result: Inhibited PHF6 aggregation and ameliorates eye neurodegeneration Drosophila overexpressing the human tau protein (htau). |
| References |
| Molecular Formula | C21H15ClN2O4 |
|---|---|
| Molecular Weight | 394.81 |